Status:

COMPLETED

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

National Alliance for Research on Schizophrenia and Depression

Abbott

Conditions:

Schizophrenia

Schizoaffective Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The major objective of this proposal is to test the hypothesis that the addition of divalproex sodium to an atypical antipsychotic drug other than clozapine will significantly improve: a) cognition; a...

Detailed Description

Cognitive function is one of the most critical deficits in schizophrenia and schizoaffective disorder. It has been found that cognitive dysfunction may be even more important than positive or negative...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Male or female, age 18-65
  • Diagnostic and Statistical Manual (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder
  • Treated with olanzapine, aripiprazole, ziprasidone, quetiapine or risperidone monotherapy for at least three months prior to enrollment
  • Able to provide written consent
  • Exclusion criteria
  • Primary DSM-IV diagnosis other than schizophrenia or schizoaffective disorder
  • Treatment with any antipsychotic other than olanzapine, aripiprazole, ziprasidone, quetiapine or risperidone in the past three months
  • Treatment with a mood stabilizer or an antidepressant continuously in the past three months. Patients who have had it for less than two weeks continuously will be permitted to enter.
  • Pregnant or lactating females

Exclusion

    Key Trial Info

    Start Date :

    March 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2008

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT00306475

    Start Date

    March 1 2006

    End Date

    April 1 2008

    Last Update

    June 27 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Psychiatric Hospital at Vanderbilt

    Nashville, Tennessee, United States, 37212

    Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? | DecenTrialz